Leerink upgrades this downbeat biotech, says investors should buy the dip
- Posted on February 5, 2025
- By CNBC
- 1 Views
Leerink upgrades this downbeat biotech, says investors should buy the dip
Analyst David Risinger upgraded shares to outperform. He also raised his price target to $834 from $762.
